Price movement over the last 24 hours
Amplitude Inc vs Koninklijke Philips NV — how do they compare? Amplitude Inc trades at $9.21 (market cap $1.22B), while Koninklijke Philips NV trades at $27.4 (market cap $26.63B). The key difference: Koninklijke Philips NV is far larger — about 21.8× Amplitude Inc's market cap, and Koninklijke Philips NV pays a 3.7% dividend while Amplitude Inc pays none. Which is the better fit depends on your goals.
| AMPL | PHG | |
|---|---|---|
Market Cap | $1.22B | $26.63B |
Sector | Technology | Health |
52-Week High | $13.04 | $32.91 |
52-Week Low | $5.61 | $24.03 |
Enterprise Value | $1.05B | $32.90B |
Dividend Yield | — | 3.7% |
Signals from Pluang's Aura AI — not financial advice
AMPL trades at $9.18, down 2.13% over the past day, with a bullish technical signal from moving averages but bearish oscillators. Revenue growth is strong, reaching $343.21M in 2025, yet the company remains unprofitable with a net income margin of -25.11%. Analyst consensus is bullish with a $9.25 price target, though recent news includes multiple law firm fraud investigations and a Bank of America downgrade citing profitability concerns.
The outlook hinges on AMPL's ability to translate robust revenue growth into profitability amid competitive pressures. Investment opportunity lies in potential margin expansion and market share gains, but risks include ongoing legal scrutiny, execution challenges, and persistent negative cash flows. The stock's near-term direction will likely be driven by upcoming earnings results and clarity on the fraud allegations.
Royal Philips (PHG) trades at $27.40, up 0.51% today, with a bullish technical signal despite mixed moving averages. The company shows improving fundamentals with net income turning positive to $895 million in 2025 after previous losses, supported by strong operational cash flow of $1.17 billion. Recent FDA clearances for AI-powered medical devices and strategic healthcare partnerships highlight growth initiatives. Analyst consensus leans neutral with 40.9% buy ratings amid stable revenue around $17.8 billion.
PHG presents a recovery story with margin expansion and AI innovation driving upside potential, though execution risks and debt levels near 25% of assets warrant caution. The stock's 24.1 P/E appears reasonable if earnings growth sustains, but investors should monitor competitive pressures in healthcare technology and macroeconomic impacts on capital spending.
Trailing returns across standard periods
Latest headlines on both assets
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →